Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Reprod Toxicol ; 101: 81-92, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33713778

RESUMO

Redox regulation during metazoan development ensures that coordinated metabolic reprogramming and developmental signaling are orchestrated with high fidelity in the hypoxic embryonic environment. Valproic acid (VPA), an anti-seizure medication, is known to increase markers of oxidation and also increase the risk of neural tube defects (NTDs) when taken during pregnancy. It is unknown, however, whether oxidation plays a direct role in failed neural tube closure (NTC). Spatial and temporal fluctuations in total glutathione (GSH) and total cysteine (Cys) redox steady states were seen during a 24 h period of CD-1 mouse organogenesis in untreated conceptuses and following exposure to VPA and the Nrf2 antioxidant pathway inducer, 1,2-dithiole-3-thione (D3T). Glutathione, glutathione disulfide (GSSG), and Cys, cystine (CySS) concentrations, measured in conceptal tissues (embryo/visceral yolk sac) and fluids (yolk sac fluid/amniotic fluid) showed that VPA did not cause extensive and prolonged oxidation during the period of NTC, but instead produced transient periods of oxidation, as assessed by GSH:GSSG redox potentials, which revealed oxidation in all four conceptal compartments at 4, 10, and 14 h, corresponding to the period of heartbeat activation and NTC. Other changes were tissue and time specific. VPA treatment also reduced total FITC-Ab clearance from the medium over 3 h, indicating potential disruption of nutritive amino acid supply. Overall, these results indicated that VPA's ability to affect cellular redox status may be limited to tissue-specific windows of sensitivity during the period of NTC. The safety evaluation of drugs used during pregnancy should consider time and tissue specific redox factors.


Assuntos
Anticonvulsivantes/toxicidade , Antineoplásicos/toxicidade , Embrião de Mamíferos/efeitos dos fármacos , Tionas/toxicidade , Tiofenos/toxicidade , Ácido Valproico/toxicidade , Aminoácidos/metabolismo , Animais , Cisteína/metabolismo , Embrião de Mamíferos/metabolismo , Feminino , Glutamato-Cisteína Ligase/genética , Glutamato-Cisteína Ligase/metabolismo , Glutationa/metabolismo , Heme Oxigenase-1/genética , Heme Oxigenase-1/metabolismo , Troca Materno-Fetal , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Camundongos , NAD(P)H Desidrogenase (Quinona)/genética , NAD(P)H Desidrogenase (Quinona)/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Organogênese/efeitos dos fármacos , Oxirredução , Gravidez
2.
ChemMedChem ; 13(4): 321-337, 2018 02 20.
Artigo em Inglês | MEDLINE | ID: mdl-29327456

RESUMO

With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a sought-after target in the pharmaceutical industry. Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases. These efforts culminated in the discovery of N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-[(tetrahydro-2H-pyran-4-yl)methyl]-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide (CD12681), a potent inverse agonist with in vivo activity in an IL-23-induced mouse skin inflammation model.


Assuntos
Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares/agonistas , Psoríase/tratamento farmacológico , Sulfonamidas/química , Administração Tópica , Animais , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Agonismo Inverso de Drogas , Humanos , Concentração Inibidora 50 , Interleucina-17/metabolismo , Interleucina-23/farmacologia , Queratinócitos/citologia , Queratinócitos/efeitos dos fármacos , Queratinócitos/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares/metabolismo , Psoríase/patologia , Dermatopatias/induzido quimicamente , Dermatopatias/tratamento farmacológico , Dermatopatias/patologia , Relação Estrutura-Atividade , Sulfonamidas/metabolismo , Sulfonamidas/uso terapêutico , Células Th17/citologia , Células Th17/efeitos dos fármacos , Células Th17/metabolismo
3.
J Med Imaging Radiat Oncol ; 57(6): 633-43, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24283550

RESUMO

Adhesive capsulitis is one of the most common conditions affecting the shoulder; however, early clinical diagnosis can be challenging. Treatment is most effective when commenced prior to the onset of capsular thickening and contracture; consequently, the role of imaging is increasing. The aim of this review is to demonstrate the typical imaging appearances of adhesive capsulitis and to examine some of the evidence regarding each of these imaging modalities. An evaluation of the various management options available to the clinician is also presented.


Assuntos
Bursite/diagnóstico , Bursite/terapia , Descompressão Cirúrgica/métodos , Imageamento por Ressonância Magnética/métodos , Manipulações Musculoesqueléticas/métodos , Bloqueio Nervoso/métodos , Ultrassonografia/métodos , Artroplastia/métodos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA